| 【Company Research】Giant Biogene (2367 HK) - Strong Performance in 2024 |
| 【Company Research】Weichai Power (2338 HK/000338 CH) - Strong engine margin expansion in 2024; 55% dividend payout ratio a record high |
| 【Company Research】Haidilao (6862 HK) - Potential store and margin expansion ahead |
| 【Company Research】Atour Lifestyle (ATAT US) - Cautious outlook but downside is limited |
| 【Company Research】WuXi Biologics (2269 HK) - Strong demand to drive growth acceleration in 2025 |
| 【Company Research】Nongfu Spring (9633 HK) - Flat FY24 earnings, with FY25 set for double-digit growth |
| 【Company Research】3SBio (1530 HK) - Earnings beat, rich pipeline promises future growth |
| 【Company Research】SenseTime (20 HK) - Gen AI business maintains momentum on increased AI investment |
| 【Company Research】Meidong Auto (1268 HK) - High inventory turnover strategy still working now |
| 【Company Research】BYDE (285 HK) - 4Q24 earnings dragged by one-off expenses; auto/AI/Apple ramp to drive growth in 2025 |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
